Table 1 Demographic and headache baseline characteristics of patients who received at least one dose of erenumab and concerned by effectiveness and safety assessment (n = 140)
Characteristics | N = 140 |
|---|---|
Gender | |
 Female | 115 (82.1%) |
 Male | 25 (17.9%) |
Age | 50.9 ± 11.4 |
MHDs | 22.5 ± 7.3 |
MMDs | 19.6 ± 7.4 |
Migraine form | |
 MEHF | 16 (11.4%) |
 CM | 124 (88.6%) |
Medication overuse | |
 Yes | 127 (90.7%) |
 No | 13 (9.3%) |
HAD | |
 Anxiety | 9.5 ± 4.4 |
 Depression | 7.5 ± 4.8 |
 HIT-6 | 68.0 ± 5.9 |
 EQ-5D | 0.55 ± 0.30 |
Concurrent oral preventive treatment | |
 Yes | 4 (2.9%) |
 No | 136 (97.1%) |
Psychiatric comorbidities | |
 Yes | 69 (49.3%) |
 No | 71 (50.7%) |
Other comorbidities | |
 Yes | 38 (27.1%) |
 No | 102 (72.9%) |
Triptan responsiveness | |
 Yes | 106 (75.7%) |
 No | 34 (24.3%) |